Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 8/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770503 | 0.88 | AMY1A (0.42) | BRD4ALPLALPIALPGAMY1A | |
| SCHEMBL14770682 | 0.88 | AMY1A (0.41) | BRD4ALPLALPIALPGAMY1A | |
| SCHEMBL14770488 | 0.87 | BRD4 (0.43) | BRD4ALPLALPIALPGAMY1A | |
| SCHEMBL14770733 | 0.84 | IDO1 (0.42) | BRD4AMY1A | |
| SCHEMBL14770492 | 0.84 | AMY1A (0.41) | ALPLALPIALPGAMY1A | |
| SCHEMBL14770501 | 0.79 | MLKL (0.46) | BRD4ALPLALPIALPG | |
| SCHEMBL29212574 | 0.79 | KDM4E (0.51) | ALPLALPIALPGTSHR | |
| SCHEMBL14770723 | 0.77 | MLKL (0.45) | BRD4ALPLALPIALPGAMY1A | |
| SCHEMBL17910618 | 0.77 | ROCK2 (0.46) | BRD4TSHR | |
| SCHEMBL14770545 | 0.77 | CACNA1C (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | BRD4 1580/4885ALPL 4272/4885ALPI 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.